2026-10-19T00:02:31Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/request

oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/122102026-10-18T21:13:22Zopenairedrivercom_ebyu_10000col_ebyu_10001

Effect of curcumin on lipid profile, fibrosis, and apoptosis in liver tissue in abemaciclib-administered ratsHuyut, ZübeyirUçar, BünyaminAltındağ, FikretYıldızhan, KenanHuyut, Mehmet TahirAbemaciclibapoptosiscurcuminfibrosislipid profileliver damageAnimalsbcl-2-Associated X ProteinCaspase 3CholesterolLiverLiver DiseasesRatsTriglyceridesTumor Necrosis Factor-alphaaspartate aminotransferasedimethyl sulfoxidehigh density lipoproteinlactate dehydrogenaselow density lipoproteinprotein Baxtriacylglyceroltumor necrosis factoranimal experimentanimal modelanimal tissueArticleaspartate aminotransferase blood levelblood samplingcholesterol blood levelAbemaciclib (ABEM) is an important antitumor agent for breast cancer treatment. However, the side-effects of ABEM are unclear in the liver. This study investigated the protective effect of curcumin (CURC) on liver damage caused by ABEM. The rats were divided into five groups with eight animals in each group; Control, DMSO (150 µL for per rats), CURC, 30 mg/kg/day), ABE (26 mg/kg/day), and ABE + CURC (26 mg/kg/day ABE, 30 mg/kg/day) groups. Injections were administered daily for 28 days. The levels of AST, LDH, HDL, LDL, triglyceride, and total cholesterol in serum, and hepatic tissue fibrosis, caspase-3, Bax, and TNF-α expression were higher in the ABE group compared to the control group (p < 0.05). Also, these parameters in the ABEM + CURC group were lower than in the ABE group (p < 0.05). The results showed that ABE administration could cause liver damage and increase fibrosis in the liver. In addition, it was shown that co-administration of CURC with ABE could suppress the levels of AST, LDH, HDL, LDL, triglyceride, and total cholesterol in serum, and fibrosis, caspase-3, Bax, and TNF-α expressions in the liver. These data are the first in the literature. Therefore, the administration of CURC following ABE may be a therapeutic agent in preventing liver damage. © 2022 Informa UK Limited, trading as Taylor & Francis Group.Taylor and Francis Ltd.2023Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/12210https://doi.org/10.1080/01480545.2022.21350070148-0545enDrug and Chemical Toxicologyinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/12210